ISPOR 27. YILLIK AVRUPA KONGRESİ (BARSELONA/İSPANYA)

Cost-Effectiveness of Asciminib for the Post-2 Tyrosine Kinase Inhibitor Treatment of Chronic Phase Chronic Myeloid Leukaemia in Türkiye

Cost of Chronic Myeloid Leukaemia in Türkiye: Results of a Delphi Panel Approach

Cost of Hepatocellular Carcinoma in Türkiye: Results of a Delphi Panel Analysis

Epidemiological Disparities and Risk Factors of Esophageal Cancer in Türkiye: A Systematic Review

 ISPOR 26. YILLIK AVRUPA KONGRESİ (KOPENHAG/DANİMARKA)

COST-EFFECTIVENESS of OFATUMUMAB in TREATMENT OF RELAPSING MULTIPLE SCLEROSIS in TÜRKİYE  

COST-EFFECTIVENESS of RIBOCICLIB PLUS A NON-STEROIDAL AROMATASE INHIBITOR for the TREATMENT of PRE and PERI-MENOPAUSAL WOMEN with HR+/HER2 ADVANCED BREAST CANCER in TÜRKİYE 

 

ISPOR 25. YILLIK AVRUPA KONGRESİ (VİYANA/AVUSTURYA) 

 

COST EFFECTIVENESS OF ALPELISIB PLUS FULVESTRANT FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH PIK3CA MUTANT HR+/HER2- ADVANCED BREAST CANCER IN TURKEY

 

COST EFFECTIVENESS OF COLLAGEN LAMININ-BASED DERMAL MATRIX COMBINED WITH RESVERATROL MICROPARTICLES IN TREATMENT OF DIABETIC FOOT ULCER TREATMENT IN TURKEY

 

(COST EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF IMPLEMENTING THE FIRST PILLAR OF PATIENT BLOOD MANAGEMENT WITH INTRAVENOUS FERRIC CARBOXYMALTOSE ON THE TURKISH HEALTHCARE SYSTEM

 

COST EFFECTIVENESS OF SIPONIMOD FOR SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS IN TURKEY

 

 

ISPOR 21. YILLIK AVRUPA KONGRESİ (BARSELONA/İSPANYA) 

COST EFFECTIVENESS OF DERMABOND^TM PRINEO^TM SKIN CLOSURE SYSTEM IN HIP AND KNEE ARTHROPLASTY IN TURKEY

 

ISPOR 21. YILLIK ULUSLARARASI TOPLANTI (WASHINGTON DC/ABD)

COMPARISON OF SUGAMMADEX AND NEOSTIGMINE USE IN TERMS OF COST SAVINGS IN HOSPITALS IN TURKISH HEALTHCARE SETTING
(PSY26, May 2016, ISPOR 21st Annual International Meeting, Washington DC, USA ) 

TREATMENT ALGORITHM AND DIRECT COSTS OF TREATMENT OF HR+/HER2- POST MENOPAUSAL ADVANCED/METASTATIC BREAST CANCER PATIENTS IN TURKEY
(PCN70, May 2016, ISPOR 21st Annual International Meeting, Washington DC, USA ) 

 

ISPOR 20. YILLIK AVRUPA KONGRESİ (GLASGOW/İSKOÇYA) 

 

BUDGET IMPACT OF ALTEPLASE IN TREATMENT OF ACUTE ISCHEMIC STROKE IN TURKEY

COST-EFFECTIVENESS OF CONTOUR CURVED CUTTER STAPLER IN LOW ANTERIOR RESECTION IN TURKEY

COST EFFECTIVENESS OF DURAGRAFT AS A VEIN GRAFT TREATMENT IN CORONARY ARTERY BYPASS GRAFTING IN TURKEY

LOCAL PRODUCTION POLICIES IN THE TURKISH PHARMACEUTICAL MARKET

COST-EFFECTIVENESS OF BARIATRIC SURGERY IN TURKEY: FROM A LONG-TERM PERSPECTIVE

COST EFFECTIVENESS OF PENTARAY HIGH DENSITY MAPPING CATHETER IN TREATMENT OF VENTRICULAR TACHYCARDIA IN TURKEY

 

ISPOR 19. YILLIK AVRUPA KONGRESİ (VİYANA/AVUSTURYA)

 

ADHERENCE TO GOLD CRITERIA STRATEGY IN TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) PATIENTS: COST IMPLICATIONS IN TURKEY
(PRS14, October 2016, ISPOR 19th Annual European Congress, Vienna, Austria) 

DIRECT COST OF HIV/AIDS IN TURKEY
(PIN29, October 2016, ISPOR 19th Annual European Congress, Vienna, Austria) 

DIRECT COSTS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN TURKEY: A PANEL APPROACH
(PRS23, October 2016, ISPOR 19th Annual European Congress, Vienna, Austria) 

DIRECT COSTS OF EPILEPSY IN TURKEY: A PANEL APPROACH
(PND35, October 2016, ISPOR 19th Annual European Congress, Vienna, Austria) 

INDIRECT COST OF HIV/AIDS: RESULTS OF A SURVEY FROM A TURKISH RESEARCH CENTER
(PIN27, October 2016, ISPOR 19th Annual European Congress, Vienna, Austria) 

INDIRECT COSTS OF EPILEPSY IN TURKEY: COST OF THE DISEASE IN TERMS OF WORK LOSS
(PND34, October 2016, ISPOR 19th Annual European Congress, Vienna, Austria) 

INDIRECT COSTS OF STROKE IN TURKEY
(PCV66, October 2016, ISPOR 19th Annual European Congress, Vienna, Austria) 

 

ISPOR 18. YILLIK AVRUPA KONGRESİ (MİLANO/İTALYA)

 

COST EFFECTIVENESS OF SODIUM OXYBATE IN TREATMENT OF CATAPLEXY IN PATIENTS WITH NARCOLEPSY IN TURKEY
(PND50, November 2015, ISPOR 18th Annual European Congress, Milan, Italy) 

COST OF FAMILIAL MEDITERRANEAN FEVER (FMF) DISEASE IN TURKEY
(PSY43, November 2015, ISPOR 18th Annual European Congress, Milan, Italy) 

COST SAVING STUDY OF FIVE GRASS POLLEN SLIT TABLET VERSUS SCIT'S & SYMPTOMATIC TREATMENT
(PRS22, November 2015, ISPOR 18th Annual European Congress, Milan, Italy) 

COST-EFFECTIVENESS OF CERTOLIZUMAB PEGOL FOR THE TREATMENT OF AXIAL SPONDYLOARTHRITIS IN TURKEY
(PMS65, November 2015, ISPOR 18th Annual European Congress, Milan, Italy) 

DIRECT TREATMENT COSTS OF STROKE IN TURKEY
(PCV86, November 2015, ISPOR 18th Annual European Congress, Milan, Italy) 

HOW PRICING AND REIMBURSEMENT POLICIES AFFECT THE BUDGET IMPACT OF THE TREATMENT OF SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS IN TURKEY
(PMS56, November 2015, ISPOR 18th Annual European Congress, Milan, Italy) 

LOCAL COST STUDY OF TREATMENT OF VENOUS THROMBOEMBOLISM IN TURKEY
(PCV87, November 2015, ISPOR 18th Annual European Congress, Milan, Italy) 

 

ISPOR 17. YILLIK AVRUPA KONGRESİ (AMSTERDAM/HOLLANDA)

 

AVAILABILITY OF RISK SHARING AGREEMENTS IN THE TURKISH PHARMACEUTICAL SECTOR
(PHP65, November 2014, ISPOR 17th Annual European Congress, Amsterdam, The Netherlands) 

COST-ANALYSIS OF CHRONIC IDIOPATHIC URTICARIA DISEASE
(PSS16, November 2014, ISPOR 17th Annual European Congress, Amsterdam, The Netherlands) 

COST-EFFECTIVENESS OF OMALIZUMAB IN CHRONIC IDIOPATHIC URTICARIA REFRACTORY TO H1-ANTIHISTAMINES IN TURKEY
(PSS3, November 2014, ISPOR 17th Annual European Congress, Amsterdam, The Netherlands) 

COST-EFFECTIVENESS OF USE OF BARRICAID® IN LUMBAR DISCECTOMY SURGERY IN TURKEY
(PMS44, November 2014, ISPOR 17th Annual European Congress, Amsterdam, The Netherlands) 

DEVELOPMENT OF HTA IN TURKEY
(PHP244, November 2014, ISPOR 17th Annual European Congress, Amsterdam, The Netherlands) 

 

ISPOR 16. YILLIK AVRUPA KONGRESİ (DUBLİN/İRLANDA)

 

COST OF OBESITY AND ECONOMIC VALUE OF OBESITY SURGERY FOR TURKEY (CEVOS-T)
(PSY24, November 2013, ISPOR 16th Annual European Congress, The Convention Centre Dublin)